Last updated: February 15, 2026
Product Overview
NDC 70000-0555 refers to Zirabev (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab). It is indicated for multiple cancers, including colorectal, lung, and ovarian cancers. Approved by the FDA in February 2021 for oncological applications, Zirabev is manufactured by Mylan (now part of Viatris) and gained market authorization as a cost-effective alternative to Avastin.
Market Context
The global bevacizumab market was valued at approximately $7.4 billion in 2022 and is estimated to grow at a compound annual growth rate (CAGR) of around 4.5% through 2028 [1]. Biosimilars entered the U.S. market in earnest from 2021, with Zirabev positioned as a primary competitor to the originator in oncology indications.
Market Penetration and Adoption Trends
- Market share: Zirabev captured 12-15% of the U.S. bevacizumab market within 18 months post-launch, driven by indications in colorectal and non-small cell lung cancers.
- Pricing: The biosimilar's list price is about $5,000–$6,500 per vial, compared to Avastin’s $9,000–$11,000.
- Reimbursement: Payers favor biosimilars due to cost savings, leading to rapid formulary adoption.
- Physician adoption: Growing confidence in biosimilars, supported by multiple label expansions and biosimilar-specific clinical data, accelerates market share gains.
Pricing Projections
| Year |
Estimated Average Price per Vial |
Notes |
| 2023 |
$5,000–$6,000 |
Current market price range |
| 2024 |
$4,800–$5,800 |
Slight downward pressure due to increased competition |
| 2025 |
$4,500–$5,500 |
Further price erosion as biosimilar options expand |
| 2026 |
$4,300–$5,200 |
Price stabilization expected with increased volume |
Price reduction is anticipated owing to competition from other biosimilars and potential patent expirations of the originator.
Revenue Projections
- 2022: ~$250 million in the U.S.
- 2023: ~$330 million, assuming rapid market penetration
- 2024: ~$410 million
- 2025: ~$470 million, with continued growth but diminishing incremental gains
By 2026, revenues are projected to plateau around $500 million, accounting for market saturation and price competition.
Market Challenges and Risks
- Patent litigations: The originator has active patent protections, delaying some biosimilar introductions in certain regions.
- Physician and patient acceptance: Trust in biosimilar efficacy remains solid but is not universal.
- Reimbursement policies: Fluctuations could impact price and volume.
Regulatory and Competitive Dynamics
- Several biosimilars, including Amgen’s MVasi (bevacizumab-awwb), have entered the market, increasing competitive pressure.
- Global markets, especially Europe and Asia, might adopt biosimilars at different rates, affecting overall revenue.
Summary of Key Factors Influencing Market and Price
- Biosimilar price sensitivity
- Payer and formulary dynamics
- Patent exclusivity periods
- Clinical guideline updates
- Competitive biosimilar entries
Key Takeaways
- Zirabev is positioned as a cost-effective alternative to Avastin with significant early market penetration.
- Price per vial is projected to decline gradually through 2026, influenced by increased biosimilar competition.
- Revenue growth will be steady through 2025, plateauing thereafter due to market saturation.
- Market expansion hinges on payer acceptance and regulatory approvals outside the U.S.
- Ongoing patent disputes and clinical adoption patterns will shape long-term market share and profitability.
FAQs
1. How does Zirabev compare to Avastin in terms of clinical efficacy?
Clinical data show equivalent efficacy between Zirabev and Avastin in approved indications, aligning with FDA biosimilar requirements.
2. What is the main driver of pricing for biosimilars like Zirabev?
Market competition, payer policies, and negotiated discounts primarily drive biosimilar prices downward.
3. When are additional biosimilars expected to enter the market?
Multiple biosimilars are anticipated to launch through 2024-2025, increasing competitive pressure.
4. What are the key regulatory considerations affecting Zirabev?
Regulatory hurdles include patent litigations in major markets; approvals outside the U.S. vary based on regional biosimilar policies.
5. How might global markets influence Zirabev's revenue?
Growth in Europe, Asia, and Latin America could significantly expand revenue streams, especially if biosimilar adoption accelerates.
Citations
[1] MarketWatch. "Bevacizumab Market Size, Share & Industry Analysis," 2022.
